Drug Profile
Adalimumab biosimilar - Synermore Biologics
Alternative Names: SYN-060Latest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator Synermore Biologics
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 06 Jan 2023 Adalimumab biosimilar is still in phase II trial for Rheumatoid arthritis (SC) (Synermore Biologics pipeline, January 2023)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Australia (SC, Injection)
- 20 Jan 2021 Phase-II clinical trials in Rheumatoid arthritis (SC) (Synermore Biologics pipeline, January 2021)